Wire
Invivyd Completes Enrolment in Phase 3 Symptomatic COVID-19 Trial
Invivyd (IVVD) said Monday that it has completed patient enrolment in the phase 3 Declaration trial, evaluating its VYD2311 antibody for the prevention of symptomatic COVID-19.Top-line results from the study are still expected in late Q3, the company said.The Declaration study is evaluating the prevention of symptomatic COVID-19 at three months, with either a single dose or monthly doses of VYD2311, administered via intramuscular injection, compared to placebo, Invivyd said.Shares of the company were up 2.6% in Monday's premarket activity.Price: $1.17, Change: $+0.03, Percent Change: +2.63%
$IVVD
